Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$120,315 Mln
Revenue (TTM)
$48,194 Mln
Net Profit (TTM)
$7,053 Mln
ROE
0.4 %
ROCE
10.6 %
P/E Ratio
17.1
P/B Ratio
6.5
Industry P/E
--
EV/EBITDA
10.3
Div. Yield
4.2 %
Debt to Equity
2.6
Book Value
$9.1
EPS
$3.5
Face value
--
Shares outstanding
2,036,473,705
CFO
$84,297.00 Mln
EBITDA
$102,671.00 Mln
Net Profit
$29,834.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb (BMY)
| 10.1 | -1.6 | 10.9 | -1.0 | -3.7 | -0.9 | -0.3 |
|
BSE Sensex*
| -12.2 | -11.2 | -12.0 | -1.2 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb (BMY)
| -4.6 | 10.1 | -28.7 | 15.4 | 2.9 | 0.4 | 27.7 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb (BMY)
|
59.4 | 120,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 |
| 208.3 | 388,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 351.5 | 197,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 | |
| 918.1 | 881,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 | |
| 141.3 | 179,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 | |
| 237.3 | 582,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 920.4 | 116,133.4 | 397,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 | |
| 114.5 | 285,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 149.8 | 296,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 | |
| 27.3 | 151,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.... The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. Read more
CEO & Chairman
Dr. Christopher S. Boerner Ph.D.
CEO & Chairman
Dr. Christopher S. Boerner Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bristol-Myers Squibb Company (BMY) is $59.37 (NYSE) as of 18-Mar-2026 16:17 EDT. Bristol-Myers Squibb Company (BMY) has given a return of -3.72% in the last 3 years.
The P/E ratio of Bristol-Myers Squibb Company (BMY) is 17.08 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.61
|
5.96
|
|
2024
|
-12.88
|
7.05
|
|
2023
|
13.00
|
3.54
|
|
2022
|
24.15
|
4.92
|
|
2021
|
19.78
|
3.85
|
The 52-week high and low of Bristol-Myers Squibb Company (BMY) are Rs 62.89 and Rs 42.52 as of 19-Mar-2026.
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $ 120,315 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Bristol-Myers Squibb Company (BMY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.34
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.